LIMN (Liminatus Pharma) Buyback Yield %: -174.66 (As of Jul. 06, 2026)


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Buyback Yield %?

Liminatus Pharma LIMN +22.63% 13 Buyback Yield % is -174.66 as of Jul. 06, 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 741 Biotechnology companies, Liminatus Pharma ranks worse than 94.2% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Liminatus Pharma's current buyback yield was -174.66%.

Liminatus Pharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Buyback Yield % Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 -63.94

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -3.64 -23.36 -63.94 -183.32

LIMN vs GNPX, PCSA, ELAB: Buyback Yield % Comparison

For the Biotechnology subindustry, Liminatus Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liminatus Pharma Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liminatus Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Liminatus Pharma's Buyback Yield % falls into.


LIMN
13GF Score
Liminatus Pharma Inc LIMN
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Liminatus Pharma's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 10.557) / 16.50965
=-63.94%

Liminatus Pharma's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (14.142 + 0) / 7.7145282
=-183.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -174.66 mean?
Liminatus Pharma (LIMN) has a Buyback Yield % of -174.66 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Liminatus Pharma and its competitors. According to the industry distribution chart, Liminatus Pharma ranks #698 out of 741 companies in the Biotechnology industry, placing it in the top 94.2%.
Is Liminatus Pharma's Buyback Yield % too high?
Liminatus Pharma's current Buyback Yield % is -174.66. Based on the distribution chart, Liminatus Pharma ranks #698 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Buyback Yield % compare to GNPX and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #698 out of 741 companies for Buyback Yield %. This places Liminatus Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current Buyback Yield % is -174.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Buyback Yield % of -174.66. The current Buyback Yield % is -174.66. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Buyback Yield % is -174.66 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price